IgG4-related Disease Clinical Trials

17 recruitingLast updated: May 13, 2026

There are 17 actively recruiting igg4-related disease clinical trials across 7 countries. Studies span Phase 2, Phase 1, Early Phase 1, Not Applicable, Phase 3. Top locations include Beijing, Beijing Municipality, China, Wuhan, Hubei, China, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


IgG4-related Disease Trials at a Glance

17 actively recruiting trials for igg4-related disease are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in Beijing, Wuhan, and Boston. Lead sponsors running igg4-related disease studies include Peking Union Medical College Hospital, Tongji Hospital, and Chinese PLA General Hospital.

Browse igg4-related disease trials by phase

Treatments under study

About IgG4-related Disease Clinical Trials

Looking for clinical trials for IgG4-related Disease? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new IgG4-related Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about IgG4-related Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 117 of 17 trials

Recruiting
Phase 2

Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases

Behcet's DiseaseIdiopathic Inflammatory MyopathiesIgG4-related Disease
UMC Utrecht60 enrolled6 locationsNCT06285539
Recruiting
Phase 2Phase 3

The Investigators Will Evaluate the Diagnostic Performance of [18F]-AlF-FAPI-74 PET/CT in Inflammatory Disorders and Compare it With the Current Gold Standard for Inflammation, FDG PET/CT, in Three Patient Cohort: Patients Presenting With Fever of Unknown Origin, IgG4-RD and AxSpA.

Axial Spondylarthritis (axSpA)IgG4-related DiseaseInflammation of Unknown Origin+1 more
Universitaire Ziekenhuizen KU Leuven140 enrolled1 locationNCT07535554
Recruiting
Phase 1Phase 2

Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease

IgG4-related Disease
Acepodia Biotech, Inc.30 enrolled3 locationsNCT07061938
Recruiting
Phase 2

A Study of Efgartigimod in Patients With IgG4-Related Disease

IgG4-related Disease
Stanford University5 enrolled1 locationNCT07025330
Recruiting
Phase 2Phase 3

A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease

IgG4-related Disease
Peking Union Medical College Hospital198 enrolled1 locationNCT07068165
Recruiting
Phase 2

Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease

B-cell Mediated Autoimmune DisordersIgG4-related Disease
Chinese PLA General Hospital9 enrolled1 locationNCT07148791
Recruiting
Not Applicable

A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD

IgG4-Related Diseases
Luo Yaping46 enrolled1 locationNCT07104058
Recruiting
Phase 1

A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases

Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)Inflammatory Myopathy+5 more
China Immunotech (Beijing) Biotechnology Co., Ltd.12 enrolled1 locationNCT06978647
Recruiting
Phase 1

The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases

ANCA-associated VasculitisIgG4-Related DiseasesLupus Nephritis+1 more
Nanjing University School of Medicine24 enrolled1 locationNCT06285279
Recruiting

AYLo - AutoimmunitY and Loss of y

Asthma BronchialeCOPDSarcoidosis+10 more
University of Bonn500 enrolled1 locationNCT06696027
Recruiting
Phase 2

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

Systemic Lupus ErythematosusSjogren SyndromeInflammatory Myopathy+6 more
Peking University People's Hospital50 enrolled1 locationNCT06794008
Recruiting
Not Applicable

Short-term Glucocorticoid Combined with MMF for IgG4-RD

IgG4-related Disease
Wen Zhang63 enrolled1 locationNCT06663618
Recruiting
Early Phase 1

Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease

IgG4-related DiseaseLupus Nephritis
Tongji Hospital30 enrolled1 locationNCT06497387
Recruiting
Early Phase 1

Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease

IgG4-related DiseaseLupus Nephritis
Tongji Hospital30 enrolled1 locationNCT06497361
Recruiting

Meir Medical Center Rheumatologic Biobank

Rheumatoid ArthritisSjogren's SyndromeSystemic Sclerosis+2 more
Meir Medical Center500 enrolled1 locationNCT03473912
Recruiting

A Prospective Cohort Study of IgG4RD in China

IgG4-related Disease
Peking Union Medical College Hospital1,000 enrolled1 locationNCT01670695
Recruiting

National Registry of IgG4-RD in China

IgG4-related Disease
Peking Union Medical College Hospital900 enrolled1 locationNCT03023371